PCSK9 in acute coronary syndrome: analysis of associations with clinical and laboratory characteristics
https://doi.org/10.15829/1728-8800-2020-2484
Abstract
The article discusses a literature review reflecting the importance of identifying novel biomarkers in cardiology for improving conventional methods for diagnosing and stratifying risk in patients with acute coronary syndrome (ACS). Recently, more and more studies have published on such markers, in particular, on the proprotein convertase subtilisin/ kexin type 9 (PCSK9). The aim of this review was to analyze the associations of PCSK9 with clinical and laboratory parameters in patients with ACS. It has been demonstrated that the PCSK9 level in acute myocardial infarction is significantly increased. In patients with ACS, the level of PCSK9 is directly related to the duration of pain, the severity of coronary artery disease, familial hypercholesterolemia and lipid parameters, as well as the severity of coronary atherosclerosis according to the SYNTAX score. It was found that statin therapy before ACS significantly affects the association of PCSK9 with lipid profile. There are conflicting data on the associations of PCSK9 with the parameters of inflammatory response in ACS, as well as isolated evidence of the positive role of anti-IL-6 receptor monoclonal antibodies in ACS patients with dyslipidemia. The impact of PCSK9 on ACS prognosis is currently unstudied.
About the Authors
Yu. A. Drenina
Center for Diagnostic and Cardiovascular Surgery;
Surgut State University
Russian Federation
Surgut
Russian Federation
Surgut
K. Yu. Nikolaev
Surgut State University;
Research Institution of Internal and Preventive Medicine
Russian Federation
Russian Federation
Surgut;
Novosibirsk
References
1. Mortality in United States, 2017: NCHS Data Brief No. 328. https://www.cdc.gov/nchs/products/databriefs/db328.htm (November 2018).
2. Cardiovascular diseases statistics: Eurostat Statistics Explained. https://ec.europa.eu/eurostat/statistics-explained/index. php?title=Cardiovascular_diseases_statistics#Deaths_from_ cardiovascular_diseases (November 2019).
3. Death rate by cause of death: Federal State Statistics Service. (In Russ.) https://www.gks.ru/incomparisons
4. Muromtseva GA, Kontsevaya AV, Konstantinov VV, et al. Prevalence of non-infectious diseases risk factors in russian population in 2012-2013 years. The results of ecvd-rf. Cardiovascular Therapy and Prevention. 2014;13(6):4-11. (In Russ.) doi:10.15829/1728-8800-2014-6-4-11.
5. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol. 2009; 29(4):431-8. doi:10.1161/ATVBAHA.108.179564.
6. The Nobel Prize in Physiology or Medicine 1985: The Nobel Prize. https://www.nobelprize.org/prizes/medicine/1985/summary/
7. Kukharchuk VV, Bajan SS. Proprotein convertase subtilisin/keksin type 9 (PCSK9) — control the expression of low-density lipoprotein receptor. The Journal of Atherosclerosis and Dyslipidemias. 2013;2(11):19-25. (In Russ.)
8. Popova AB, Nozadze DN, Sergienko IV. The Role of PCSK9 in Coronary Vascular Disease Development. The Journal of Atherosclerosis and Dyslipidemias. 2016;3:5-14. (In Russ.).
9. Drenina YA. Protein convertase subtilisin/kexin type 9 as marker reflecting the degree of lipid metabolisim imbalance and it’s role in coronary vascular disease progression. Vestnik SurGU Medicina. 2019;2(40):100-4. (In Russ.)
10. Almontashiri NA, Vilmundarson RO, Ghasemzadeh N, et al. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies. PLoS One. 2014;9(9):e106294. doi:10.1371/journal.pone.0106294.
11. Gencer B, Montecucco F, Nanchen D, et al. Prognostic value of PCSK9 levels in patients with acute coronary syndromes. European Heart Journal. 2016;37(6):546-53. doi:10.1093/eurheartj/ehv637.
12. Lim GB. Low prognostic utility of measuring PCSK9 levels in ACS. Nature Reviews Cardiology. 2016;13:62-3. doi:10.1038/nrcardio.2015.197.
13. Cariou B, Guerin P, Le May C, et al. Circulating PCSK9 levels in acute coronary syndrome: Results from the PC-SCA-9 prospective study. Diabetes Metab. 2017;43(6):529-35. doi:10.1016/j. diabet.2017.07.009.
14. Bae KH, Kim SW, Choi YK, et al. Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome. Diabetes Metab J. 2018;42(3):207-14. doi:10.4093/dmj.2017.0081.
15. Ueland T, Kleveland O, Michelsen AE, et al. Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction. Open Heart. 2018;5(2):e000765. doi:10.1136/openhrt-2017-000765.
Review
For citations:
Drenina Yu.A., Nikolaev K.Yu. PCSK9 in acute coronary syndrome: analysis of associations with clinical and laboratory characteristics. Cardiovascular Therapy and Prevention. 2020;19(4):2484. (In Russ.) https://doi.org/10.15829/1728-8800-2020-2484
Views:
661
Email this article 
